Last reviewed · How we verify
Duspatalin
Duspatalin is a Small molecule drug developed by Guy Boeckxstaens. It is currently in Phase 3 development.
Duspatalin, also known as Alverine citrate, is used to treat conditions such as hypertension, portal hypertension, and irritable bowel syndrome. It is studied in combination with other medications like Carvedilol for the treatment of portal hypertension in patients with liver cirrhosis.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Duspatalin |
|---|---|
| Sponsor | Guy Boeckxstaens |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Ebastine Versus Mebeverine in IBS Patients (PHASE3)
- Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders (PHASE3)
- Enteric-Coated Peppermint Oil Versus Standard Antispasmodic in SLC6A4 (5-HTTLPR) Carriers With Irritable Bowel Syndrome. (NA)
- The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot Study (PHASE2)
- Carvedilol and Alverine in Portal Hypertension (PHASE2, PHASE3)
- The Safety and Efficacy of Alverine in the Treatment of Cirrhotic Portal Hypertension (PHASE2, PHASE3)
- The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis (PHASE2, PHASE3)
- To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duspatalin CI brief — competitive landscape report
- Duspatalin updates RSS · CI watch RSS
- Guy Boeckxstaens portfolio CI
Frequently asked questions about Duspatalin
What is Duspatalin?
Who makes Duspatalin?
What development phase is Duspatalin in?
Related
- Manufacturer: Guy Boeckxstaens — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing